Vertex says FDA reviews CASGEVY label expansion to younger children with sickle cell, beta thalassemia
Share
Listen to the news
Vertex says FDA reviews CASGEVY label expansion to younger children with sickle cell, beta thalassemia
  • Vertex filed to expand CASGEVY to younger children, with FDA review underway in the US.
  • Regulatory submissions also completed in Saudi Arabia and the UK to extend use below age 12.
  • CASGEVY is currently cleared in several markets for eligible patients aged 12 and older with SCD or transfusion-dependent beta thalassemia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260610130971) on June 11, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending